Zucara Therapeutics receives the support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to advance their long-term therapeutic approach to prevent hypoglycemia in patients with diabetes. In addition, the company has received support from MaRS Innovation and the Centre for Drug Research and Development.
Recently defining its lead drug candidate, ZT-01, this support will enable Zucara to conduct critical evaluation work to advance it though preclinical testing formulation and manufacturing for human clinical trials. CDRD’s Analytical Chemistry division is completing these activities while efficacy studies are underway at the laboratory of project collaborator, Dr. Michael Riddell at York University.
“The continued support from NRC-IRAP has been instrumental in funding the R&D required to define our lead drug candidate and advance ZT-01 to what we hope will be an effective therapy for patients with diabetes,” says Michael Midmer, chief executive officer, Zucara Therapeutics. “We also recognize and appreciate the ongoing support from our founding investors MaRS Innovation and CDRD who continue to help us make Zucara a success.”
This year Zucara is focusing on additional testing, safety, efficacy and toxicology studies required for human testing with the aim of starting a Phase 1 clinical trial in 2019.